GE Healthcare Executes Recombinant Protein L License from Affitech

Affitech A/S and GE Healthcare Life Sciences have announced that GE Healthcare Life Sciences has executed an exclusive license for the worldwide marketing and sales of products containing recombinant Protein L, granted by Affitech in a patent and know-how license agreement.

Under the terms of the agreement, GE Healthcare Life Sciences agrees to pay Affitech a royalty of the net sales of all related products sold by GE Healthcare Life Sciences.

Martin Welschof, Managing Director of Affitech commented, “I am delighted that GE Healthcare Life Sciences has executed the granted license to recombinant Protein L, which has proved to be the only naturally occurring affinity protein useful for working with both non-protein A binding antibodies and antibody fragments. By executing this license GE Healthcare Life Sciences is now in a position to commercialize and widen access to this innovative recombinant Protein L technology.”

Commenting on the execution of the recombinant Protein L license, Catarina Flyborg, General Manager BioProcess Products at GE Healthcare Life Sciences said, “This is an important step forward for GE Healthcare Life Sciences and will enable us to develop new technologies to help solve some of the most difficult challenges faced by our customers in biopharmaceutical manufacturing and in protein science research.”